Table 3.

Breakdown of the Different Cohorts of the EV301 Trial

Cohort	Disease Setting	Intervention	Patients, No.
A	First-line cisplatin-ineligible mUC	EV + pembrolizumab	50
B (optional)	Second-line cisplatin-ineligible mUC	EV + pembrolizumab	33
D	First-line mUC	EV + cisplatin	6–12
E	First-line mUC	EV + carboplatin	6–12
F (optional)	First-line or second-line mUC	EV + gemcitabine	6–12
G	First-line mUC	EV + platinum (cisplatin or carboplatin) plus pembrolizumab	50
H	Neoadjuvant treatment for MIBC	EV	20
J	Neoadjuvant treatment for MIBC	EV + pembrolizumab	20

Abbreviations: mUC, metastatic urothelial carcinoma; EV, enfortumab vedotin; MIBC, muscle-invasive bladder cancer.